By Karen Roman
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer’s Disease.
The nomination comes after the company exercised its option with JCR Pharmaceuticals as part of a previously signed agreement, it stated.
Register for our weekly newsletter HERE
“We are advancing IND-enabling activities toward a mid-2027 IND submission and are excited about the potential to offer patients and caregivers more effective and convenient therapeutic options,” said Jim Doherty, Acumen President and Chief Development Officer.
READ MORE
Aurora Cannabis Generates 55% Revenue Outside Canada as Medical Sales Surge – Quarterly Update Report
Contact:
Click HERE to follow us on LinkedIn
